Alzheimer's disease (AD) is the most common form of dementia. It is characterized by
extracellular deposition of a specific protein, beta-amyloid peptide fibrils, and is …

A 72-year-old man seeks consultation at the urging of his wife for increasing difficulty with
memory over the past 2 years. Clients at his brokerage firm have expressed concern about …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and
cognitive loss, and represents the leading cause of dementia in elderly people. Besides the …

Introduction Clinicians need to predict prognosis of Alzheimer's disease (AD), and
researchers need models of progression to develop biomarkers and clinical trials designs …

More than a decade after the first approval of the use of acetylcholine esterase inhibitor on
patients with Alzheimer's disease, we still not have a single treatment or combination …

Currently approved medications to treat cognitive deficits in Alzheimer's disease are
targeting relatively late neurotransmission alterations and, thus, new approaches are …

ML Berthier, et al www. neurologia. com Rev Neurol 2010; 51 (8): 449-450 450 moria)[10].
La evidencia indica que la EA es una condición heterogénea en su expresión clínica y …

The reduction of AChE is seen in advanced stages of the disease, as is a reduction of
choline acetyltransferase (Bender, 2005). B uty rylcholinesterase (BuChE), which is related …

阿尔茨海默症治疗药物临床应用研究-[维普官方网站]-www.cqvip.com-维普网  我的维普 购物车
充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术 …